McKesson's stock appears undervalued, trading at 18 times forward earnings and free cash flow. See why MCK is a Hold.

In the latest trading session, McKesson (MCK) closed at $586.08, marking a -1.1% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 0.88%. Meanwhile, the Dow ...

McKesson (MCK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

McKesson MCK has started 2025 on a positive note, with the stock climbing 4% so far in January as investors remain optimistic ...

McKesson shared that on Dec. 30, 2024, it closed the transaction announced in September 2024 to sell its Canada-based Rexall and Well.ca businesses to Birch Hill Equity Partners, a Canadian ...

McKesson (NYSE:MCK – Get Free Report) had its price objective cut by Citigroup from $713.00 to $677.00 in a research note ...

For the ninth year, CMS has named McKesson a Qualified Clinical Data Registry approved to participate in the Merit-based ...

The Supreme Court is meeting for oral arguments this morning in Food and Drug Administration v. R.J. Reynolds Vapor Co. and ...

McKesson (MCK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) reported today that on December 30, 2024 it has closed the transaction announced in September 2024 to sell its Canada-based Rexall ...

Beyond funding, McKesson Amplify also will provide resources, strategic support and other tools to help state pharmacy associations achieve their local and state advocacy goals in 2025.